Free Trial
NASDAQ:BLUE

bluebird bio 9/27/2024 Earnings Report

bluebird bio logo
$4.97 0.00 (0.00%)
As of 06/2/2025

bluebird bio EPS Results

Actual EPS
-$8.40
Consensus EPS
-$8.00
Beat/Miss
Missed by -$0.40
One Year Ago EPS
N/A

bluebird bio Revenue Results

Actual Revenue
$16.10 million
Expected Revenue
$16.09 million
Beat/Miss
Beat by +$10.00 thousand
YoY Revenue Growth
N/A

bluebird bio Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

bluebird bio's Q1 2025 earnings is scheduled for Tuesday, August 12, 2025

Conference Call Resources

bluebird bio Earnings Headlines

Analysts Set bluebird bio, Inc. (NASDAQ:BLUE) PT at $44.60
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
See More bluebird bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bluebird bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bluebird bio and other key companies, straight to your email.

About bluebird bio

bluebird bio (NASDAQ:BLUE) is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company leverages its proprietary lentiviral-based platform to deliver functional copies of genes into patients’ cells, aiming to address the underlying causes of monogenic disorders. bluebird bio’s lead programs include a treatment for transfusion-dependent β-thalassemia and a therapy for cerebral adrenoleukodystrophy, with additional candidates advancing in sickle cell disease, metachromatic leukodystrophy and oncology indications.

Founded in 1992 as Genetix Pharmaceuticals and rebranded in 2013, bluebird bio has established a global footprint with operations in Cambridge, Massachusetts, and European research facilities. Its multidisciplinary teams encompass gene therapy research, process development, clinical operations and regulatory affairs. The company’s manufacturing network supports both ex vivo autologous cell therapies and in vivo gene editing approaches, reflecting its commitment to scalable production and broad patient access.

Beyond its core pipeline, bluebird bio collaborates with academic institutions and industry partners to accelerate discovery and optimize clinical outcomes. These partnerships span translational research, vector engineering and long-term follow-up studies aimed at evaluating durability and safety. Through these efforts, the company seeks to expand its platform’s versatility across rare genetic diseases and selected oncology applications, including CAR-T cell therapies for hematologic malignancies.

bluebird bio is guided by a leadership team composed of seasoned executives and scientific experts with extensive experience in biotechnology and pharmaceutical sectors. Supported by a board of directors that includes innovators in gene therapy and drug development, the company is committed to advancing its mission of delivering potentially curative treatments to patients with high unmet medical needs.

View bluebird bio Profile

More Earnings Resources from MarketBeat